Literature DB >> 29491455

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.

Christopher Maximilian Arends1, Joel Galan-Sousa1, Kaja Hoyer1, Willy Chan1, Marten Jäger2, Kenichi Yoshida3, Ricarda Seemann4, Daniel Noerenberg1, Nils Waldhueter1, Helga Fleischer-Notter1, Friederike Christen1, Clemens A Schmitt1, Bernd Dörken1, Uwe Pelzer1, Marianne Sinn1, Tomasz Zemojtel2, Seishi Ogawa3, Sven Märdian4, Adrian Schreiber5, Annegret Kunitz1, Ulrike Krüger2, Lars Bullinger1, Elena Mylonas1, Mareike Frick1, Frederik Damm6,7.   

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) occurs in an age-related manner and associates with an increased risk of hematologic cancer, atherosclerotic disease, and shorter overall survival. Little is known about the cell of origin, repartition patterns of clonal mutations within the hematopoietic differentiation tree, and its dynamics under evolutionary pressure. Using targeted sequencing, CHIP was identified in 121 out of 437 elderly individuals (27.7%). Variant allele frequencies (VAFs) of 91 mutations were studied in six peripheral blood cell fractions. VAFs were significantly higher in monocytes, granulocytes, and NK-cells compared to B- or T cells. In all cases with available bone marrow material, mutations could be identified in Lin-CD34+CD38- HSCs with subsequent expansion to myeloid primed progenitors. In 22 patients with solid cancer receiving (radio-)chemotherapy, longitudinal study of 32 mutations at 121 time points identified relative VAF changes of at least 50% in 13/32 mutations. VAFs of DNMT3A, were stable in 12/13 cases (P < .001). Cancer patients with a clonal mutation other than DNMT3A required more often red blood cell transfusions and dose reductions. Our results provide novel insights into cellular distribution of clonal mutations, their dynamics under chemotherapy, and advocate for systematic analyses for CHIP in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29491455     DOI: 10.1038/s41375-018-0047-7

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

Review 1.  Aging and Hematopoiesis.

Authors:  Emma M Groarke; Neal S Young
Journal:  Clin Geriatr Med       Date:  2019-05-09       Impact factor: 3.076

2.  Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis.

Authors:  Elina K Cook; Terumi Izukawa; Sherylan Young; Gili Rosen; Mina Jamali; Liying Zhang; Dylan Johnson; Eva Bain; Jamie Hilland; Christina K Ferrone; Jonah Buckstein; Janika Francis; Bushra Momtaz; Amy J M McNaughton; Xudong Liu; Brooke Snetsinger; Rena Buckstein; Michael J Rauh
Journal:  Blood Adv       Date:  2019-08-27

3.  Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.

Authors:  Tracy Murphy; Jinfeng Zou; Georgina S Daher-Reyes; Andrea Arruda; Vikas Gupta; Caroline J McNamara; Mark D Minden; Aaron D Schimmer; Hassan Sibai; Karen W L Yee; Mariam Korulla; Tracy Stockley; Suzanne Kamel-Reid; Dawn Maze; Anne Tierens; Scott V Bratman; Andre C Schuh; Steven M Chan
Journal:  Blood Adv       Date:  2019-08-13

4.  Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Christopher Maximilian Arends; Marlene Weiss; Friederike Christen; Claudia Eulenberg-Gustavus; Anthony Rousselle; Ralph Kettritz; Kai-Uwe Eckardt; Willy Chan; Kaja Hoyer; Mareike Frick; Lars Bullinger; Markus Bieringer; Adrian Schreiber; Frederik Damm
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

5.  Stem cell donors should not be screened for clonal hematopoiesis.

Authors:  Christopher J Gibson; R Coleman Lindsley
Journal:  Blood Adv       Date:  2020-02-25

6.  Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients.

Authors:  Christine R C Zhang; Darren Nix; Martin Gregory; Matthew A Ciorba; Elizabeth L Ostrander; Rodney D Newberry; David H Spencer; Grant A Challen
Journal:  Exp Hematol       Date:  2019-12-05       Impact factor: 3.084

Review 7.  Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis.

Authors:  Pradeep Natarajan; Siddhartha Jaiswal; Sekar Kathiresan
Journal:  Circ Genom Precis Med       Date:  2018-07

8.  Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.

Authors:  Stephan R Bohl; Laura K Schmalbrock; Imke Bauhuf; Tatjana Meyer; Anna Dolnik; Martin Szyska; Tamara J Blätte; Sarah Knödler; Linda Röhner; Denise Miller; Miriam Kull; Christian Langer; Hartmut Döhner; Anthony Letai; Frederik Damm; Dirk Heckl; Lars Bullinger; Jan Krönke
Journal:  Blood Adv       Date:  2021-05-11

9.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors:  Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2018-07-17       Impact factor: 14.808

Review 10.  The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.

Authors:  Mariam T Nawas; Johannes Schetelig; Frederik Damm; Ross L Levine; Miguel-Angel Perales; Sergio A Giralt; Marcel R VanDenBrink; Maria E Arcila; Ahmet Zehir; Elli Papaemmanuil; Anja Klussmeier; Alexander H Schmidt; Stephanie Maiwald; Kelly L Bolton; Roni Tamari
Journal:  Blood Rev       Date:  2020-08-24       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.